While the majority of somatic mutations in the EGFR and ErbB2 kinases increase the kinase activity, a number of the classified ErbB4 cancer mutants have been shown to inhibit or reduce the kinase activity (Tvorogov et al., 2009). Here, ERBB2 is linked to cancer.